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Aim 
Intraplaque angiogenesis is an important contributor to atherosclerotic plaque growth and instability. 
Angiogenic signals induce endothelial cells (ECs) to switch their metabolism to being highly glycolytic, 
enabling their growth and division. Glycolytic modulation by inhibition of the glycolytic activator 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) has been shown to reduce 
angiogenesis. The objective of this study was to identify novel anti-angiogenic compounds with a 
potential to efficiently modulate (inhibit) angiogenesis.  
 
Methods 
Using the human EC line EA.hy926, we studied the effects of PFKFB3 inhibition with 3PO, a weak 
competitive inhibitor of PFKFB3, and of two potent self-synthesized phenoxindazole analogues (PA-1 
and PA-2) on glycolysis, proliferation, migration, matrix metalloproteinase (MMP) activity, and 
capillary tube formation. The latter experiment was also performed using primary human umbilical 
vein endothelial cells (HUVEC). Moreover, gene expression of important markers related to 
angiogenesis were measured at mRNA level by real-time PCR.  
 
Results 
PFKFB3 inhibition with all three tested compounds significantly reduced glycolytic activity. While PA-
1 and PA-2 suppressed capillary tube formation in both cell groups, 3PO did not have any effect in 
EA.hy926 ECs and even an inducing effect in the HUVECs. Accordingly, PA-1 and PA-2 markedly 
inhibited EC migration, proliferation and wound closing capacity which are essential for neovessel 
formation. Moreover, these inhibitors downregulated gelatinase gene expression up to 6-fold, as well 
reduced the activity of proMMP-9 and MMP-2 up to 50% and 30% compared to control, respectively. 
Gene expression analysis revealed that the PA compounds downregulated PFKFB3 expression whilst 
3PO did not. Similarly, markers of migration and angiogenesis, such as CCL5, VCAM-1, VEGFA and 
VEGFR2, were also markedly reduced (up to 10-fold) by the PA compounds.  
 
Conclusions 
These findings suggest that PFKFB3 inhibition with PA compounds may interfere with key pro-
angiogenic functions, such as endothelial migration, proliferation and capillary-like structure 
formation and this exerts a multitarget anti-angiogenic activity. Hence, PFKFB3 inhibition with PA 
compounds is a promising therapeutic approach to promote plaque stability.  
